Navigation Links
Dave Anderson and William Thomsen Join SRI International's Center for Advanced Drug Research to Lead Programs in Proteomics and Metabolic Disease Drug Discovery
Date:2/23/2011

MENLO PARK, Calif., Feb. 23, 2011 /PRNewswire/ -- SRI International, an independent nonprofit research and development organization, announced today that two new principal scientists, Dave Anderson, Ph.D., and William Thomsen, Ph.D., have joined its Center for Advanced Drug Research (CADRE) in Shenandoah Valley, Virginia.

Dr. Anderson will serve as principal scientist in CADRE's proteomics group. He has more than 20 years of experience applying mass spectrometry and proteomics methods to a variety of scientific problems. At SRI, he will apply those methods to set up biomarker analytics for specific disease areas and study host-pathogen interactions and pathogen drug resistance mechanisms.

Prior to joining SRI, Dr. Anderson was senior director of proteomics at Catalyst Biosciences and research fellow for proteomics and target discovery at Rigel Pharmaceuticals. Earlier, he headed the protein chemistry department at Khepri Pharmaceuticals and then at Arris Pharmaceutical following its acquisition of Khepri. In between his positions in the biotech industry, he was a research professor at the University of Oregon.

Dr. Anderson received his Ph.D. from the University of Oregon. He has authored more than 60 publications and holds 42 U.S. patents.

Dr. Thomsen will serve as principal scientist in CADRE's metabolic diseases group, where he will lead research pertaining to metabolic diseases.

He joins SRI with more than 25 years of experience in pharmaceutical drug discovery, with an emphasis on target validation, assay development, high throughput screening, and molecular pharmacology. He has experience with several classes of discovery targets, including G protein coupled receptors, within multiple therapeutic areas, including: disorders of the central nervous system; endocrine, metabolic, cardiovascular, and immunological diseases; and cancer. Most recently, he served as the director of molecular pharmacology at Arena Pharmaceuticals.

Dr. Thomsen received his Ph.D. from the University of Michigan and was a postdoctoral fellow at the University of Washington.

About SRI's Center for Advanced Drug Research (CADRE)

SRI established the Center for Advanced Drug Research (CADRE) to improve the productivity of the pharmaceutical industry, help our nation respond to biothreats, and develop life-saving treatments for rare and neglected diseases. CADRE's mission is to create new therapeutics, diagnostics, and vaccines for infectious and other diseases and for biodefense. CADRE combines and partners with SRI's well-established expertise in drug discovery, computational biology, and preclinical development with a new proteomics laboratory to develop these solutions.

About SRI's Biosciences Division

SRI's Biosciences division carries out basic research, drug discovery, and drug development, and provides contract (CRO) services. SRI has all of the resources necessary to take R&D from "Idea to IND"®—from initial discovery to the start of human clinical trials—and specializes in cancer, immunology and inflammation, infectious disease, and neuroscience. SRI's product pipeline has yielded marketed drugs, therapeutics currently in clinical trials, and additional programs in earlier stages. In its CRO business, SRI has helped government and commercial clients and partners advance many drugs into patient testing. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International  

Silicon Valley-based SRI International, a nonprofit research and development organization, performs sponsored R&D for governments, businesses, and foundations. SRI brings its innovations to the marketplace through technology licensing, new products, and spin-off ventures. Commemorating its 65th anniversary in 2011, SRI is known for world-changing innovations in computing, health and pharmaceuticals, chemistry and materials, sensing, energy, education, national defense, and more.


'/>"/>
SOURCE SRI International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TransTech Medical Solutions Expands Offering to MD Anderson Cancer Center to Include Outsourced Medical Transcription and Editing Services
2. Statement of Ben Anderson, Esq., Regarding Denial of Wyeths En Banc Petition to Sixth Circuit Court of Appeals in Major Drug Regulation Pre-emption Case
3. Researchers at MD Anderson Show That Positron Emission Mammography (PEM) Helps Evaluate Early Response to Neoadjuvant Chemotherapy
4. Frank Phillips, Paul Anderson and Federico Girardi Join SI-BONEs Medical Advisory Board
5. Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center
6. NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer
7. Help is Here Express Arrives in Anderson, Seneca
8. HS-7 Document Regarding Research @ M. D. Anderson Orlando
9. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
10. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
11. Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):